Literature DB >> 33310785

Balloon-mounted stenting for ICAS in a multicenter registry study in China: a comparison with the WEAVE/WOVEN trial.

Kaijiang Kang1,2,3, Yong Zhang4, Jie Shuai5, Changchun Jiang6, Qiyi Zhu7, Kangning Chen8, Li Liu9, Baomin Li10, Xiangqun Shi11, Lianbo Gao12, Yajie Liu13, Feng Wang14, Yongli Li15, Tieyan Liu16, Hongbo Zheng17, Dapeng Mo2,3,18, Feng Gao2,3,18, Lei Feng19, Yilong Wang1,2,3, YongJun Wang1,2,3, Zhongrong Miao20,3,18, Ning Ma20,3,18.   

Abstract

BACKGROUND: The outcome of deploying balloon-mounted stents for symptomatic intracranial atherosclerotic stenosis (ICAS) has not been fully investigated. In this study we evaluate the safety and long-term outcome of using balloon-mounted stents to treat symptomatic ICAS in comparison with the WEAVE/WOVEN study.
METHODS: In a multicenter registry study of stenting for symptomatic intracranial artery stenosis in China, 159 patients treated with an intracranial balloon-mounted stent approved by the China Food and Drug Administration were evaluated. The morphological features of the lesions were categorized by Mori classification. The endpoints, including periprocedural and long-term clinical and radiological outcomes, were the same as those in the WEAVE/WOVEN study.
RESULTS: In the present study the mean percent stenosis before and after stenting was 84.0% and 6.1%, respectively. The proportions of Mori A, Mori B, and Mori C lesions were 33.3%, 52.2%, and 14.5%, respectively. The 72-hour rates of stroke and mortality after the procedure were 0%. The 1-year rates of any stroke, ischemic stroke, hemorrhagic stroke, and death were 6.3% (10/159), 5.7% (9/159), 0.6% (1/159), and 0.6% (1/159), respectively. The 1-year rate of in-stent restenosis (ISR) was 23.4% (15/64). The rate of ISR in Mori C lesions (53.8%, 7/13) was significantly higher than that in Mori A (15.8%, 3/19) or Mori B lesions (15.6%, 5/32) (p=0.024).
CONCLUSIONS: The short-term and long-term outcomes of using a balloon-mounted stent for symptomatic ICAS with focal and non-angular lesions (Mori A and B type) and smooth arterial access were comparable to the results of the WEAVE/WOVEN trial. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  atherosclerosis; balloon; stenosis; stent; stroke

Year:  2020        PMID: 33310785     DOI: 10.1136/neurintsurg-2020-016658

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  4 in total

1.  Comparison of Drug-Eluting Stent With Bare-Metal Stent in Patients With Symptomatic High-grade Intracranial Atherosclerotic Stenosis: A Randomized Clinical Trial.

Authors:  Baixue Jia; Xuelei Zhang; Ning Ma; Dapeng Mo; Feng Gao; Xuan Sun; Ligang Song; Lian Liu; Yiming Deng; Xiaotong Xu; Yong Zhang; Zengpin Liu; Sheng Guan; Fan Zhang; Bing Li; Hongbo Zheng; Xinfeng Liu; Yajie Liu; Kangning Chen; Jie Shuai; Jieqing Wan; Jun Wang; Xiangqun Shi; Tianxiao Li; Binge Chang; David S Liebeskind; Wengui Yu; Zhongrong Miao
Journal:  JAMA Neurol       Date:  2022-02-01       Impact factor: 18.302

2.  Intracranial Angioplasty with Enterprise Stent for Intracranial Atherosclerotic Stenosis: A Single-Center Experience and a Systematic Review.

Authors:  Bowen Sun; Chao Xu; Pei Wu; Man Li; Shancai Xu; Chunlei Wang; Xiangyu Liu; Yeping Ling; Huaizhang Shi
Journal:  Biomed Res Int       Date:  2021-04-17       Impact factor: 3.411

3.  Effect of Ginkgolide in Ischemic Stroke patients with large Artery Atherosclerosis: Results from a randomized trial.

Authors:  Yi Dong; Jingyu Zhang; Yanxia Wang; Lihong Zhao; Runhui Li; Chunhua Wei; Qingke Bai; Lishu Wan; Liping Sun; Shejun Feng; Mingyao You; Chun Wang; Hongtian Zhang; Qing He; Ming Yu; Qiang Dong
Journal:  CNS Neurosci Ther       Date:  2021-10-22       Impact factor: 5.243

4.  Long-Term Outcome of Enterprise Stenting for Symptomatic ICAS in a High-Volume Stroke Center.

Authors:  Rongrong Cui; Long Yan; Kaijiang Kang; Ming Yang; Ying Yu; Dapeng Mo; Feng Gao; Yongjun Wang; Xin Lou; Zhongrong Miao; Ning Ma
Journal:  Front Neurol       Date:  2021-06-17       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.